Lung diseases
GSK and Cambridge University Collaborate on $65M Research Initiative to Combat Immune-Related Kidney and Lung Diseases
GSK, Cambridge University, Immune-related diseases, Kidney diseases, Lung diseases, Research collaboration, $65M deal
AN2 Therapeutics Cuts 50% of Staff and Discontinues Epetraborole Program for MAC Lung Disease
AN2 Therapeutics, epetraborole, MAC lung disease, Phase II/III trial, workforce reduction, restructuring, melioidosis, Chagas disease
Savara Raises $100 Million Following Lung Disease Treatment Breakthrough
Savara, Lung Disease, $100 Million Raise, Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Treatment
Insmed’s Stocks Skyrocket Following Triumphant Phase III Results for Brensocatib in Bronchiectasis Treatment
Insmed, brensocatib, bronchiectasis, Phase III trial, lung disease, stock surge, New Drug Application, FDA approval, market value